Back to Search
Start Over
Sexual function and sex hormones in breast cancer patients
Sexual function and sex hormones in breast cancer patients
- Publication Year :
- 2018
-
Abstract
- Breast cancer patients (BCP) are at risk of female sexual dysfunction (FSD). Our aim was to clarify the effects of treatment strategies, and steroid hormones levels on FSD. We enrolled 136 BCP (46.9 ± 0.8 years), and 122 completed questionnaires. BCP were divided into four groups: 22 women with advanced breast cancer on neoadjuvant therapy (NAT), 48 on adjuvant therapy (AT), 30 taking hormonal therapy (HT) and 22 with metastatic cancer on first line chemotherapy (FLT). Fifty-eight healthy women (43 ± 2.8 years) were enrolled as controls. FSD was evaluated by FSFI, and sexual distress was assessed with FSDS-R. We have collected demographic data, laboratory values, and LH, FSH, total testosterone (T), and estradiol (E2) levels. BCP showed a prevalence of FSD of 69%, total FSFI score was 17. FSDS-R was 8.3. FSD had a prevalence of 72 % in NAT, 65% in AT, 77% in metastatic BCP under FLT, 67% in HT, compared with a prevalence of 20% in controls. BCP showed lower E2 than normal values, as well as T. LH and FSH were significantly elevated than normal values. Total FSFI score was positively correlated with T in 122 BCP, no significant correlation was found between E2 and FSFI. Significant differences were found between NAT and HT in lubrication, pain domains and total FSDS-R score, AT and HT in pain domain, AT and NAT in lubrication domain. BCP are at high risk of developing FSD both for treatment choice and hormonal status, but they have not sexually related personal distress.
- Subjects :
- Adult
Oncology
medicine.medical_specialty
Sexual Behavior
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
Female sexual dysfunction
Breast Neoplasms
FSD
03 medical and health sciences
0302 clinical medicine
Endocrinology
Breast cancer
Surveys and Questionnaires
Internal medicine
FSDS-R
Prevalence
medicine
Adjuvant therapy
Humans
Chemotherapy
Testosterone
Sexual Dysfunctions, Psychological
Neoadjuvant therapy
030219 obstetrics & reproductive medicine
Estradiol
business.industry
Cancer
FSFI
Luteinizing Hormone
Middle Aged
medicine.disease
Sexual Dysfunction, Physiological
030220 oncology & carcinogenesis
Hormonal therapy
Female
Follicle Stimulating Hormone
Sexual function
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....c53af282f1896268e6a596e7ecab7645